Short-term delisting risk is removed, which may stabilize trading. However, with no fundamental updates and recent insider selling, traders should remain cautious. Monitor for future acquisition announcements or clinical updates as next catalysts.
Price Chart
Executive Summary
Tevogen Bio (TVGN) announced it has regained compliance with Nasdaq's $1.00 minimum bid price requirement, resolving a delisting concern from September 2025. The company reiterated its strategic focus on AI-driven drug development and potential acquisitions, but provided no new financial or clinical data.
Key Facts
- Tevogen regained compliance with Nasdaq's $1.00 minimum bid price rule after previously being out of compliance since September 23, 2025.
- No financial results, clinical updates, or transaction details were disclosed.
- Company reiterated strategic goals around AI (Tevogen.AI), immunotherapy (ExacTcell™), and potential acquisitions.
- Forward-looking statements dominate the release; no material operational or financial milestones were announced.
Financial Impact
No immediate financial impact — resolution of listing status only.
Risk Factors
- Lack of financial or clinical transparency — company remains pre-revenue with no near-term commercial catalysts disclosed.
- Recent insider selling (3 sells totaling $7K) may signal limited confidence despite listing compliance.
- Forward-looking statements carry high execution risk given company’s small size and limited operating history.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3262508 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 30, 2026 27d ago | 8-K | $6.72 | awaiting T+60 | — | $6.28 (−6.55%) |
Sep 16, 2026 5w ago | SC 13D/A | $7.71 | awaiting T+60 | — | $6.28 (−18.55%) |
Sep 16, 2026 5w ago | SC 13D/A | $7.71 | awaiting T+60 | — | $6.28 (−18.55%) |
Sep 16, 2026 5w ago | 8-K | $7.71 | awaiting T+60 | — | $6.28 (−18.55%) |
Jun 26, 2026 17w ago | EFFECT | $7.00 $7.43 | ▼ −6.14% | ▼ −1.66% | $6.28 (+10.29%) |
Jun 12, 2026 19w ago | S-3 | $10.02 $7.34 | ▲ +26.75% | ▲ +27.75% | $6.28 (+37.33%) |
Jun 9, 2026 20w ago | Press Release | $10.75 $7.17 | ▼ −33.30% | ▼ −37.12% | $6.28 (−41.58%) |
May 28, 2026 21w ago | Press Release | $8.04 $6.75 | ▼ −16.04% | ▼ −17.78% | $6.28 (−21.89%) |
May 21, 2026 22w ago | Press Release | $11.57 $6.58 | ▼ −43.10% | ▼ −47.40% | $6.28 (−45.70%) |
Mar 25, 2026 30w ago | Press Release | $5.18 $9.79 | ▲ +88.90% | ▲ +75.44% | $6.28 (+21.24%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers